Baltimore Fire union raises concerns about downgrade of 4 medical units
According to IAFF Local 734, the move could impact emergency responses and patient care in the city.
"Every second counts in a medical emergency," said Matthew Coster, President of IAFF Local 734. "Reducing ALS coverage in Baltimore means fewer units equipped with the tools and training to handle life-threatening incidents like cardiac arrest, stroke, and major trauma. This change puts patients at greater risk."
Downgrading Baltimore medic units
Coster said the city's decision to downgrade four units is in response to staffing issues and overtime constraints at the fire department. The downgrades could make those challenges worse, the union leader said.
"When we're already at strained resources and maxed out on a daily basis, we don't want to go backward, we want to keep moving forward and get ALS units on the street where they need to be," Coster said.
According to the union, ALS units are trained to administer advanced care during emergency responses, while BLS units have fewer capabilities.
ALS units can provide airway management, deliver medication and monitor cardiac health. According to Coster, the downgrade could mean it takes longer for the proper personnel to get on scene.
"When you're trying to save a life, time is your enemy," Coster said. "When it comes to trying to fight a fire to ALS interventions, fast is the best way that you wanna do it."
Coster also emphasized that 911 call volume is extremely high in the city.
He hopes his message will convince the mayor and city council to "properly fund the fire department and give us the money that we need to keep these units on the street, to properly staff and train and retain people."
"This is not about finger-pointing," Coster said. "We believe the Fire Chief and department leadership are doing the best they can under difficult circumstances. But we owe it to our residents to speak up when decisions are made that could delay care or jeopardize outcomes."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
2 days ago
- Newsweek
Watch: Moment Woman With ALS Recovers Voice With AI
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Debbie Lopez lost her voice to a muscle-weakening disease, but with the help of new artificial intelligence (AI) technology, she is speaking to her family again, Monroe Community Hospital (MCH) in Rochester, New York, confirmed to Newsweek. Why It Matters Lopez, who has been a patient at MCH since February, was diagnosed with ALS (amyotrophic lateral sclerosis) in 2019. ALS is a disease that affects the nerve cells in the body, causing the muscles to become weak and can lead to paralysis and loss of voice. No singular cause has been identified for most causes of ALS, with some research into factors that may be linked, such as heredity, environmental exposures, and diet, among others. About 30,000 people in the United States are living with ALS, according to estimates from the Centers for Disease Control and Prevention, which notes that tracking the disease can be challenging. AI technology is rapidly transforming society, reshaping jobs, productivity and advancements across sectors, including medicine. What to Know Several years ago, Lopez, 39, started a YouTube channel, Living with Lemons, to document her health journey, raise awareness, and provide comfort to others going through a similar experience. The channel has ended up being able to give Lopez her voice back, as speech pathologist Jaime Spencer, who provides care to Lopez at MCH explained, "We were able to get her voice from using her YouTube channel," adding, "and from there they were able to clone anything that she wants to say." The AI voice, which mirrors Lopez's, can now mimic anything Lopez types, thanks to the content from her YouTube videos and the technology's ability to replicate speech. MCH shared with Newsweek a video of Lopez breaking into a smile as she hears her voice from the device, saying in what sounds just like her, "Hi, I am Debbie Lopez." A screen grab of a Monroe Community Hospital video showing Debbie Lopez, a patient with ALS, hearing her voice from AI. A screen grab of a Monroe Community Hospital video showing Debbie Lopez, a patient with ALS, hearing her voice from AI. Monroe Community Hospital Lopez uses an Eyegaze device to control what the AI says, allowing her to direct and select items with her eyes, send messages and surf the web, among other features. "Cameras on the device track her eye movements and she can look at different parts of her monitor for either letters, words, or popular phrases or presets she has on her communications device," an MCH spokesperson told Newsweek in an email Wednesday. In the MCH video explaining Lopez's health journey and the use of the AI, Spencer said, "This new software and this new technology has been amazing because it allows patients and individuals to preserve some of the most intimate parts of them and what makes you you, is your voice." Lopez, through the AI, says in the video, "Even if I can't make a sound, I still have a voice." Lopez and her team at MCH are working on preserving her voice for her three children and family members by reading and recording some of her favorite children's books. What Happens Next Lopez remains in high spirits despite the severity of her disease, saying, "It's broken everyone who loves me and everyone I love, but it hasn't broken me," and adding, "I get to see the best in everyone." AI is increasingly being used in medical settings, from diagnostics and predictive analytics to assisted surgeries and the development of new treatments. "ALS can be pretty isolating. Patients lose function of much of their body parts. Anything that helps restore a sense of normalcy is a huge benefit," a MCH spokesperson told Newsweek.
Yahoo
2 days ago
- Yahoo
Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development
Researchers propose new royalty-based investment model to bridge the 'valley of death' and accelerate drug development New royalty-based investment model for ALS drug development Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH), Questrom School of Business at Boston University, and QLS Advisors have introduced a new approach to funding clinical trials for amyotrophic lateral sclerosis (ALS) therapies. The study 'Financing Drug Development via Adaptive Platform Trials,' published today in PLOS One, outlines a financing model that merges the efficiencies of adaptive platform trials — lower costs and shorter durations — with an innovative royalty-based investment structure designed to accelerate therapeutic development for ALS and other serious — also often called Lou Gehrig's disease — is a progressive, neurodegenerative disease with no cure. Despite its devastating impact, the pace of new therapy development has remained sluggish — largely due to the high cost, duration, and risks associated with traditional clinical trials. This bottleneck has often discouraged conventional investors, leaving promising research to tackle this challenge, the authors propose an investment fund that finances half the cost of an adaptive platform trial in exchange for future royalties from successful drugs that emerge from the trial. Adaptive platform trials allow multiple drug candidates to be tested simultaneously under a single master protocol and results are interpreted on a real-time basis to determine efficacy or futility. Drawing on data from the HEALEY ALS Platform Trial administered by the Healey & AMG Center for ALS and realistic assumptions, their simulated fund generated an expected return of 28%, with a 22% probability of total loss, which may be attractive to more risk-tolerant and impact-driven investors such as hedge funds, sovereign wealth funds, family offices, and philanthropists. Their findings suggest that generating returns more palatable for mainstream investors could be achieved by funding multiple platform trials simultaneously and by employing financial tools such as securitization — a method that bundles future income from assets like loans or royalties into investment study represents a multidisciplinary collaboration among physicians, clinical trial experts, and financial engineers including Annette De Mattos, Kristin Drake, Merit E. Cudkowicz, Ricardo Ortiz, Meredith Hasenoehrl, Marianne Chase, Brittney Harkey, and Sabrina Paganoni of the Sean M. Healey & AMG Center for ALS at MGH; Eugene Sorets of Questrom School of Business at Boston University; Shomesh Chaudhuri and John Frishkopf of QLS Advisors; and Joonhyuk Cho and Andrew W. Lo of MIT. Their work bridges the gap between biomedicine and capital markets, laying a new path forward for how lifesaving therapies are financed and delivered.'ALS clinical trials face significant hurdles — from high costs and long timelines to limited funding pools,' said Dr. Cudkowicz, Executive Director Mass General Brigham Neuroscience Institute and Director of the Healey & AMG Center for ALS. 'Our platform trial model has already shown that we can test more therapies more efficiently. What's still missing is sustainable financing. This novel approach could be a game-changer, enabling us to launch trials faster, include more promising therapies, and bring us closer to our shared goal: delivering effective treatments to people with ALS as quickly as possible.'Dubbed a 'Fund of Adaptive Royalties' (FAR), this model is uniquely positioned to transform how diseases like ALS are addressed, providing developers with access to shared infrastructure, centralized data analytics, and significantly reduced upfront capital requirements while offering investors a diversified, portfolio-based exposure to multiple drug candidates and the potential for high returns. While their study focused on ALS, the authors believe such a funding model could be applied to other disease areas as well, especially those with well-defined endpoints, where treatment success can be measured clearly and reliably, and few existing therapies.'This financing framework addresses one of the core issues in biomedical innovation — bridging the valley of death between discovery and delivery,' said co-author Lo, MIT Charles E. and Susan T. Harris Professor and director of MIT Sloan's Laboratory for Financial Engineering. 'By aligning incentives between investors and developers and distributing risk across a portfolio of candidates, we can unlock new sources of capital for diseases that urgently need them.' About MIT Sloan School of Management The MIT Sloan School of Management is where smart, independent leaders come together to solve problems, create new organizations, and improve the world. Learn more at About the Sean M. Healey & AMG Center for ALS at Mass General At the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, we are committed to bringing together a global network of scientists, physicians, nurses, foundations, federal agencies, and people living with ALS, their loved ones, and caregivers to accelerate the pace of ALS therapy discovery and in November 2018, the Healey & AMG Center, under the leadership of Merit Cudkowicz, MD, and a Science Advisory Council of international experts, is reimagining how to develop and test the most promising therapies to treat the disease, identify cures and ultimately prevent many clinical trials and lab-based research studies in progress right now, we are ushering in a new phase of ALS treatment and care. Together, we will find the cures. About the Boston University Questrom School of Business Founded in 1913, the Boston University Questrom School of Business is a global top-tier academic research business school. Led by Allen Questrom Professor and Dean Susan Fournier, Questrom develops business leaders who create value for the world. Questrom redefines transformational business programs, strengthens partnerships with the business community, advances the impact of research on business, and manages the school as a high-performing enterprise committed to excellence with a service mindset. Comprising a renowned full-time faculty of 165 researchers, teaching faculty, and accomplished practitioners, Questrom generates insights to address today's business challenges and prepares students with the tools they need to succeed from Day 1 in their professional lives. Questrom's portfolio of academic programs is robust and includes a Top 20 undergraduate program of over 2,200 students; distinctive MBA offerings including 900 students in a full- and part-time MBA, the affordable Online MBA and specialty MBAs in social impact, health, and digital technology; several thriving specialized masters programs in areas including business analytics, mathematical finance, and management studies; and a rigorous PhD program. More than 50,000 Questrom alumni form a powerful global network of leaders driving value creation that changes the world. QUESTROM MEANS BUSINESS. For more information, visit About QLS Advisors QLS is an investment manager that is dedicated to improving outcomes for both patients and investors. We aim to achieve these goals by applying the tools of financial engineering, including modern portfolio theory, machine learning, and healthcare finance to our discretionary investment process. At QLS, we believe that quantitative and fundamental techniques are not mutually exclusive but can be combined to build enhanced portfolios in the healthcare space. Attachment New royalty-based investment model for ALS drug development CONTACT: Casey Bayer MIT Sloan School of Management 914.584.9095 bayerc@ Brandon Chase Sean M. Healey & AMG Center for ALS 413.575.9795 bchase7@ Paul Alexander Boston University Questrom School of Business 617.470.9772 pasystem@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Yahoo
This Quebec man is losing his voice. An AI tool is helping bring it back to life
Leaning into a small microphone in a Quebec City studio, Dr. Alec Cooper takes a breath and reads out part of the often-quoted "To be, or not to be" soliloquy from Shakespeare's Hamlet. "It's pretty dramatic," said Cooper, backing away from the microphone and letting out a laugh. "I just realized, my God, it really is talking about death." It's a subject Cooper says he's been forced to think about over the past year and a half after he was diagnosed with ALS, a terminal motor neuron disease. He was initially given an average life expectancy of two to five years. The family doctor, originally from Victoria, had 1,800 patients before announcing his snap retirement last year. Staying busy renovating his house to become wheelchair accessible, Cooper has also been spending more time in front of a microphone — recording common sayings, elaborate poems and his favourite book passages as part of the process to clone his voice for when the disease progresses further. He's using AI-powered voice technology by ElevenLabs — a U.S.-based company that is offering the tech to one million people who suffer from degenerative diseases, including ALS, mouth cancer, stroke victims or those with Parkinson's disease. The AI tool allows users to input a small amount of audio which generates a voice clone with that person's natural tone and inflection when they need to rely on text-to-speech devices. Cooper started feeding the ElevenLabs bank himself at home and is getting help from professionals at the local rehab centre. "When the voice is gone, it's gone forever," said Cooper. "Thanks to this technology, the disease can't take my voice away." 'Facing it with tremendous courage' Compared to most people who have an ALS diagnosis, Cooper says he's considered a "slow progressor" and that he looks "pretty bloody good." Still, the symptoms of the illness are creeping up. He says he's starting to have trouble dressing, doing up buttons and handling utensils. His friend, Dr. Jean-Pierre Canuel, who was diagnosed with ALS 11 years ago, is further along. Canuel, a retired doctor, still gardens using his lawn mower, drives an adapted van and is dedicated to his hobby of making wooden charcuterie boards. Sitting in his motorized wheelchair, he smiles while swiping through photos of his grandchildren. It takes great effort to speak, but Canuel tells CBC that before his diagnosis, "I was a strong man." He did not have the opportunity to record his voice before his speech became severely impacted by the disease. Canuel burst into tears as Cooper greeted him in the recording area in Quebec City on a humid morning at the end of June. "It's taken his voice away, which happens to all of us," said Cooper, resting his hand on Canuel's back, consoling him. "He's facing it with tremendous courage." It's an approach Cooper is trying to adopt, he says, taking all the advice and inspiration from Canuel as possible. "I'll get all misty-eyed again, but Jean-Pierre is an incredibly courageous person. That's the way I want to be," he said, breaking down. "You have to kind of embrace it and not deny it." Improving quality of life AI voice cloning is relatively new, says Dr. Angela Genge, head of the ALS Centre of Excellence at the Montreal Neurological Institute. She says until the past decade, it wasn't widely available to patients. But multidisciplinary clinics can now offer patients voice banking relatively early on in their diagnosis, she says. "It makes a big difference for them," said Genge, a professor at McGill University. "I see AI helping with quality of life and I think it's fairly significant." She says she's used to hearing computer-generated voices articulating what patients want to say. Before the "computer age," she says patients were limited to talking using pointing cards. Now, when the disease progresses to the point of impacting speech, a patient can be equipped with devices which can formulate words and sentences in their own voice, says Sophie Dupont, a speech language pathologist for the local health authority working at the Institut de réadaptation en déficience physique de Québec. "When we're talking about text, you're literally going to be typing first [on a tablet] if you are still able," she said. The tool can also be adjusted to be used through eye control or head tracking, much like the speech-generating device used by renowned physicist Stephen Hawking, who had ALS, Dupont says. Usually, when patients arrive in her office, their ability to speak is already impaired, she says. In these cases, she relies on recordings or voicemails to power an AI voice. Having worked with Cooper for the past six months, Dupont says the AI tool is used on an exceptional basis. She says she has to balance the urgency of patients' needs with current resources. 'It's going to be a legacy' Traditionally, robotic voices available for ALS patients didn't come in all shapes and sizes, says Dustin Blank, based in Los Angeles, who leads partnerships at ElevenLabs. "Now every dialect, every language … it sounds like yourself," he said. "It is how they spoke in that same cadence, in that same emotion. And that's super powerful." He says the company's impact program is hoping to find ways to get their voice technology into the hands of people who need it most. With concerns regarding the power and security of AI, he says the company understands that voices, and the process of cloning them, are "powerful things." Taking steps to protect people's voices with password protection and voice verification, the company takes safety "very seriously," he says. Sylvie Barma, Cooper's wife of 30 years, says this tool is proof that AI is "not only bad things." While her husband is enjoying the process of using the AI tool, for Barma, the recording process is a reminder of the reality of the disease and the challenges the couple is bound to face as Cooper's health deteriorates. When she overhears him recording at home, Barma says she steps out into her sanctuary — her garden. "I just move away," she says. "We know it's coming, but I prefer not to think too much ahead. "It's going to be a legacy."
